I-Corps: Highly Sensitive Multiple Biomarker Biosensor

I-Corps：高灵敏多生物标志物生物传感器

• 批准号: 1265141
• 负责人: Ahmed Busnaina
• 金额: $ 5万
• 依托单位: Northeastern University
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-10-01 至 2013-03-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=1265141&HistoricalAwards=false
• 关键词: Corps; Highly; Sensitive; Multiple; Biomarker

Researchers plan to further develop a biosensor prototype device in order to prepare it for possible future use in medical and research fields. This prototype is an Enzyme Linked Immunosorbent Assay based biosensor that is capable of simultaneously detecting very low concentrations of various biomarkers with minimal false positives and false negatives. If successful, this will lay the foundation for early detection and monitoring of colorectal cancer that can potentially save lives and improve healthcare. Further development of the biosensor could lead to impacts in the pharmaceutical and biotechnological fields through advanced technologies of drug development and therapeutics. Additionally, if successful, the biosensor will demonstrate the effectiveness of nanotechnology approaches to overcome diagnostic challenges. This technology could aid medical professionals by furthering their knowledge on how to address low sensitivity and high specificity detection of diseases in their early stages.

研究人员计划进一步开发生物传感器原型装置，为未来可能在医疗和研究领域使用做好准备。这个原型是一种基于酶联免疫吸附分析的生物传感器，能够同时检测非常低浓度的各种生物标记物，并最大限度地减少假阳性和假阴性。如果成功，这将为早期发现和监测结直肠癌奠定基础，这可能会挽救生命和改善医疗保健。生物传感器的进一步发展可通过药物开发和治疗的先进技术在制药和生物技术领域产生影响。此外，如果成功，该生物传感器将展示纳米技术方法克服诊断挑战的有效性。这项技术可以帮助医疗专业人员进一步了解如何在疾病的早期阶段解决低敏感性和高特异性检测问题。